Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
WuXi Biologics (Cayman) Inc. (2269.HK)
Wuxi, CN
Headquartered in Wuxi, China, and established in 2014, WuXi Biologics (Cayman) Inc. delivers a comprehensive, integrated suite of services spanning the entire biologics lifecycle, from initial discovery through development to large-scale manufacturing. The company's operations have a global footprint, serving clients across the People's Republic of China, North America, Europe, and other international regions. Its diversified offerings also include specialized consultation in biopharmaceutical technology, international sales contracting, the development and deployment of advanced testing methodologies, and robust marketing and sales support. Furthermore, WuXi Biologics is involved in providing dedicated biologics clinical and manufacturing services, the production and distribution of various medical products, contract development and manufacturing (CDMO) for vaccines and associated businesses, and acting as a supplier of key materials. The firm maintains strategic partnerships with notable entities such as ImmuneOncia Therapeutics, Legochem Biosciences Inc., Worg Pharma, OncoC4, and Exelixis Inc.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.96% | +1.71% | +0.91% | -17.11% | +7.00% | +6.04% | +33.63% | -20.05% | -72.51% | +254.05% | +254.05% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 5 | 0 |
| Buy | 16 | -1 |
| Hold | 4 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+16.7% ★ Q4'25: +38.6% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%+48.7% ★ Q4'25: +134.6% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%+15.1% Q4'25: +23.6% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%+30.5% ★ Q4'25: +33.1% (vs Q4'23)
-
ROIC Biotechnology: -16.1%+13.0% ★ Q4'25: +29.4% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%-1.2% ★ Q4'25: -4.2% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.39× ★ Q4'25: 0.17× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 21 Rev. Ana. 15 EPS Ana. |
Dec 2027 21 Rev. Ana. 15 EPS Ana. |
Dec 2028 18 Rev. Ana. 14 EPS Ana. |
Dec 2029 11 Rev. Ana. 8 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.62B
est: 1.85B (-12.6%)
|
2.53B
est: 2.89B (-12.3%)
|
3.98B
est: 4.32B (-7.9%)
|
5.61B
est: 6.53B (-14.0%)
|
10.29B
est: 12.14B (-15.3%)
|
15.27B
est: 17.22B (-11.3%)
|
17.03B
est: 15.92B (+7.0%)
|
18.68B
est: 18.07B (+3.3%)
|
21.79B
est: 21.68B (+0.5%)
|
26.18B
25.92B – 26.88B
+20.7% YoY
|
30.74B
29.68B – 34.80B
+17.4% YoY
|
35.84B
35.02B – 38.84B
+16.6% YoY
|
38.54B
37.66B – 41.77B
+7.5% YoY
|
| EBITDA |
471.39M
est: 713.04M (-33.9%)
|
881.49M
est: 606.71M (+45.3%)
|
1.37B
est: 1.35B (+1.2%)
|
2.31B
est: 1.83B (+26.5%)
|
4.51B
est: 2.59B (+74.6%)
|
6.22B
est: 3.69B (+68.6%)
|
5.50B
est: 5.98B (-8.0%)
|
6.43B
est: 6.60B (-2.6%)
|
7.92B
est: 8.14B (-2.7%)
|
9.83B
9.73B – 10.09B
+20.7% YoY
|
11.54B
11.14B – 13.07B
+17.4% YoY
|
13.46B
13.15B – 14.58B
+16.6% YoY
|
14.47B
14.14B – 15.68B
+7.5% YoY
|
| EBIT |
339.38M
est: 602.36M (-43.7%)
|
737.72M
est: 579.23M (+27.4%)
|
1.15B
est: 1.13B (+1.1%)
|
2.01B
est: 1.58B (+27.1%)
|
4.03B
est: 2.24B (+80.3%)
|
5.42B
est: 3.19B (+69.8%)
|
4.33B
est: 5.01B (-13.5%)
|
4.99B
est: 5.53B (-9.8%)
|
6.65B
est: 6.82B (-2.6%)
|
8.24B
8.16B – 8.46B
+20.7% YoY
|
9.67B
9.34B – 10.95B
+17.4% YoY
|
11.28B
11.02B – 12.23B
+16.6% YoY
|
12.13B
11.85B – 13.15B
+7.5% YoY
|
| Net Income |
252.63M
est: 406.48M (-37.8%)
|
630.59M
est: 431.17M (+46.3%)
|
1.01B
est: 969.20M (+4.6%)
|
1.69B
est: 1.39B (+21.1%)
|
3.39B
est: 1.97B (+71.8%)
|
4.42B
est: 4.15B (+6.5%)
|
3.40B
est: 2.45B (+38.9%)
|
3.36B
est: 3.37B (-0.4%)
|
4.91B
est: 4.41B (+11.3%)
|
4.75B
4.69B – 6.59B
+7.7% YoY
|
6.76B
5.77B – 7.75B
+42.4% YoY
|
8.32B
6.85B – 9.78B
+23.0% YoY
|
—
— – —
-100.0% YoY
|
| SGA |
161.64M
est: 192.22M (-15.9%)
|
270.15M
est: 299.34M (-9.8%)
|
444.37M
est: 415.22M (+7.0%)
|
605.85M
est: 620.57M (-2.4%)
|
1.00B
est: 877.86M (+14.0%)
|
1.43B
est: 1.25B (+14.3%)
|
1.79B
est: 1.67B (+7.3%)
|
2.15B
est: 1.84B (+16.6%)
|
2.45B
est: 2.27B (+8.0%)
|
2.74B
2.71B – 2.82B
+20.7% YoY
|
3.22B
3.11B – 3.65B
+17.4% YoY
|
3.75B
3.67B – 4.07B
+16.6% YoY
|
4.04B
3.94B – 4.37B
+7.5% YoY
|
| EPS |
0.08
est: 0.10 (-16.8%)
|
0.16
est: 0.20 (-19.1%)
|
0.27
est: 0.30 (-9.9%)
|
0.43
est: 0.47 (-8.0%)
|
0.81
est: 0.94 (-13.6%)
|
1.06
est: 1.27 (-16.5%)
|
0.82
est: 0.59 (+38.5%)
|
0.82
est: 0.78 (+5.6%)
|
1.19
est: 1.10 (+7.7%)
|
1.38
1.12 – 1.58
+24.8% YoY
|
1.66
1.38 – 1.86
+20.3% YoY
|
1.99
1.64 – 2.34
+20.1% YoY
|
—
— – —
-100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-28 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-27 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-26 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-22 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-21 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-20 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-19 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-18 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-15 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-14 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-13 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-12 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-11 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-08 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-07 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-06 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-05 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-04 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-30 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-29 | B | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-28 | B | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-27 | B | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-24 | B | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-23 | B | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-22 | B | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-21 | B | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-20 | B | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-17 | B | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-16 | B | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-15 | B | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Zhisheng Chen | Chief Executive Officer & Executive Director | 19M | — |
| Xuejun Gu | Chief Technology Officer, Executive Vice President of Global Biologics Development Department & Executive Director | 6M | — |
| He Wang | General Counsel, Chief Compliance Officer, SVP and Head of Legal & Compliance Department | — | — |
| Jian Dong | Chief Executive Officer of WuXi Vaccines | — | male |
| Jijie Gu | Chief Scientific Officer & President of Global Biologics Research | — | — |
| Juergen Hinderer | Senior Vice President & Head of Global Engineering | — | — |
| Li Xiong | Vice President & Head of Global Human Resources | — | female |
| Angus Scott Marshall Turner | Senior Vice President and Head of Global BD & Alliance Management | — | male |
| Lina Fan | Senior Vice President & Head of Investor Relations | — | female |
| Ming Tu | Chief Financial Officer & Executive Vice President | — | male |
| William Aitchison | Senior Vice President and Head of US Operations & Key Account Executive Advisor | — | male |
| Xiaohui Liu | Executive VP & Chief Human Resources Officer | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 2269.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
